N,N-Dimethylcinnamamide

N,N-Dimethylcinnamamide

SCHEMBL3743395

CN(C)C(=O)/C=C/c1ccccc1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
TRPM8 Q7Z2W7 5/20 0.63
GLA P06280 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
MAPT P10636 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HDAC3 O15379 2/20 0.59
HDAC4 P56524 2/20 0.59
HDAC1 Q13547 2/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
PLIN1 O60240 2/20 0.59
LMNA P02545 2/20 0.59
RECQL P46063 2/20 0.59
PLIN5 Q00G26 2/20 0.59
ABHD5 Q8WTS1 2/20 0.59
ALDH1A1 P00352 2/20 0.59
TNKS O95271 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N,N-Dimethylcinnamamide SCHEMBL783551 1.00 NPC1 (0.65) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL11217696 0.89 HSD17B3 (0.55) NPC1L3MBTL1TRPM8MAPTSMN1; SMN2
SCHEMBL9590158 0.89 HDAC2 (0.59) NPC1L3MBTL1TRPM8GLATDP1
N,N-Dimethylcinnamamide SCHEMBL8702054 0.88 NPC1 (0.53) NPC1L3MBTL1TRPM8GLATDP1
N,N-Dimethylcinnamamide SCHEMBL8702052 0.88 NPC1 (0.53) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL1906844 0.86 HDAC3 (0.58) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL8993860 0.86 ALOX5 (0.67) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL10457551 0.86 ALOX5 (0.67) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL7373222 0.84 NPC1 (0.61) NPC1L3MBTL1TRPM8GLATDP1
SCHEMBL22024170 0.84 NPC1 (0.61) NPC1L3MBTL1TRPM8GLATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
EP-3553097-B1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORP (JP) 2022-05-04 EP disclosed
US-11225540-B2 Copolymer and optical film using same TOSOH CORPORATION (JP) 2022-01-18 US disclosed
WO-2021195346-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-09-30 WO disclosed
US-20210207175-A1 COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2021-07-08 US disclosed
EP-3825409-A1 COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) 2021-05-26 EP disclosed
EP-1887008-B1 THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2021-04-21 EP disclosed
EP-2501761-B1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2020-06-17 EP disclosed
US-5587486-A CONDENSATION; CARBONYLATION; HYDROLYSIS; INTERMEDIATES IN THE PRODUCTION OF MEDICINAL AND AGRICULTURAL AGENTS KURARAY CO., LTD. (JP) 1996-12-24 US disclosed
US-5574042-A ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN FUJISAWA PHARMACEUTICAL CO., LTD (JP) 1996-11-12 US disclosed
US-5563162-A CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-08 US disclosed
EP-0690054-A1 1-Amino-2-cyclohexene derivatives and production process therefor KURARAY CO., LTD. (JP) 1996-01-03 EP disclosed
EP-0622361-A1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-02 EP disclosed
CN-1089947-A New heterogeneous ring compound FUJISAWA PHARMACEUTICAL CO (JP) 1994-07-27 CN disclosed
EP-0596406-A1 Imidazo (1,2-a) Pyridines as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-05-11 EP disclosed
EP-0386142-A4 PURIFICATION BY AFFINITY BINDING TO LIPOSOMES 1991-10-30 EP disclosed
EP-0386142-A1 PURIFICATION BY AFFINITY BINDING TO LIPOSOMES NORTH CAROLINA STATE UNIVERSITY (US) 1990-09-12 EP disclosed
WO-1989004322-A1 PURIFICATION BY AFFINITY BINDING TO LIPOSOMES NORTH CAROLINA STATE UNIVERSITY (US) 1989-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 NPC1 2172/4885L3MBTL1 1916/4885TRPM8 3869/4885
US-20210207175-A1 COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF TET2, ZFX, ZFR NPC1 156/4885L3MBTL1 1806/4885TRPM8 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.